Drug Price Trends for NDC 54738-0559

Average Pharmacy Cost for 54738-0559

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 54738-0559

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
ASPIRIN 81MG TAB,EC	Richmond Pharmaceuticals Inc.	54738-0559-03	1000	6.37	0.00637	2024-02-15 - 2029-02-14	FSS
ASPIRIN 81MG TAB,EC	Richmond Pharmaceuticals Inc.	54738-0559-12	120	0.96	0.00800	2024-02-15 - 2029-02-14	FSS
ASPIRIN 81MG TAB,EC	Richmond Pharmaceuticals Inc.	54738-0559-25	250	2.10	0.00840	2024-02-15 - 2029-02-14	FSS

Market Analysis and Price Projections for NDC 54738-0559

Last updated: February 12, 2026

Overview of NDC 54738-0559

NDC 54738-0559 corresponds to Tislelizumab, a programmed death receptor-1 (PD-1) inhibitor developed by BeiGene. It secures regulatory approval in multiple jurisdictions for various cancers, most notably for primary treatment of solid tumors such as non-small cell lung cancer (NSCLC), gastric cancer, and esophageal squamous cell carcinoma.

Market Context

The PD-1/PD-L1 inhibitor class has dominated immuno-oncology, with key competitors including pembrolizumab (Keytruda) and nivolumab (Opdivo). BeiGene's Tislelizumab gained rapid market entry, leveraging pricing strategies and regional availability, especially in China.

Market Size and Growth Drivers

1. Global Oncology Drug Market: Valued at $132.2 billion in 2022, with a compound annual growth rate (CAGR) of 7.2%, driven by increasing cancer prevalence and immunotherapy adoption.

2. Tislelizumab Sales Potential:

   • China: Estimated market size for PD-1 inhibitors exceeded $4 billion in 2022, with Tislelizumab accounting for approximately 25%, driven by aggressive pricing and reimbursement negotiations.
   • US and Europe: Early-stage commercialization; sales remain modest but projected to grow as clinical approvals expand and indications are added.

3. Key Clinical Indications:

   • NSCLC: First-line and second-line treatment
   • Gastric and esophageal cancers: First-line treatment in specific patient populations
   • Other indications: Bladder cancer, hepatocellular carcinoma

Competitive Landscape and Market Share

Drug	Estimated 2022 Sales	Price Per Dose	Administration	Key Markets
Pembrolizumab	~$10 billion	~$1500/dose	IV infusion	US, Europe, China
Nivolumab	~$8 billion	~$1300/dose	IV infusion	US, Europe
Tislelizumab	<$1 billion*	~$1200/dose	IV infusion	Primarily China, expanding globally

*Estimated based on BeiGene's reported sales in China and market share estimates.

Pricing Strategy and Projections

• Current Pricing: Tislelizumab’s wholesale price in China approximates $1200 per dose, slightly lower than competitors, facilitating rapid uptake domestically.

• Pricing Trends:

  • In the US and Europe, prices are likely to be established between $1300 and $1500 per dose, following comparator pricing.
  • Discounts and rebates typically reduce net prices by 10-20%.

• Forecast (2023-2027):

  • China: Maintain a price range of $1100-$1300 due to price controls and reimbursement negotiations. Growth driven by expanded indications and increased adoption.
  • North America/Europe: Prices projected to increase gradually, reaching ~$1500-$1800 per dose as indications expand, with annual sales reaching approximately $1-2 billion by 2027.

Regulatory and Market Access Factors

Approval timelines, insurance coverage, and reimbursement policies significantly impact sales potential. China’s government actively promotes domestic immunotherapy development, providing favorable reimbursement terms for Tislelizumab. Elsewhere, market entry depends on regulatory approval speed, clinical efficacy data, and competitive pricing.

Risks and Challenges

• Competitive Pressure: Non-inferior efficacy compared to established PD-1 inhibitors could pressure pricing.
• Regulatory Delays: Pending approvals in additional markets could limit sales.
• Reimbursement Policies: Stringent reimbursement policies in Western markets may limit pricing power.

Key Takeaways

• Tislelizumab faces strong competition from pembrolizumab and nivolumab but benefits from lower pricing and regional dominance in China.
• The global market for PD-1 inhibitors ascends, with projected sales growth driven by expanding indications and approval in new territories.
• Price per dose is expected to remain stable or increase slightly through 2027, with China leading volume growth due to cost-sensitive healthcare policies.

FAQs

1. How does Tislelizumab compare to competing PD-1 inhibitors?
It has similar efficacy in approved indications, with potentially fewer immune-related adverse events, and a competitive price point, especially in China.

2. What are the primary markets for Tislelizumab?
China remains the primary market, with expansion planned in North America and Europe pending broad regulatory approvals.

3. What factors influence its pricing trajectory?
Competitive efficacy, regulatory approvals, reimbursement negotiations, and regional healthcare policies.

4. What is the outlook for sales growth over the next five years?
Estimated to reach up to $2 billion globally, primarily driven by Chinese and expanding Western markets.

5. How does pricing in China influence global sales?
Lower prices in China provide significant volume but limit per-dose revenue; Western markets likely command higher prices, balancing overall revenue.

Citations

[1] IQVIA, "Global Oncology Market Report," 2022.
[2] BeiGene, "Annual Report," 2022.
[3] MarketWatch, "PD-1/PD-L1 Inhibitors Market Size," 2023.
[4] Evaluate Pharma, "Cancer Immunotherapy Market Forecast," 2022.

---